TransCode Therapeutics, Inc. (RNAZ)
After hours:
| Previous Close | 0.4599 |
| Open | 0.4457 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.4200 - 0.4599 |
| 52 Week Range | 0.4200 - 356.0000 |
| Volume | |
| Avg. Volume | 576,570 |
| Market Cap | 2.555M |
| Beta (5Y Monthly) | -0.34 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4,144.3999 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 120.00 |
GlobeNewswireTransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors
Clinical trial expected to commence in mid-2024 to evaluate the safety and preliminary anti-tumor activity of TTX-MC138BOSTON, April 15, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, announced today that the U.S. Food and Drug Administration (FDA) has completed its review of the company’s Investigational New Drug (IND) application and concluded that the company may proceed with
- GlobeNewswire
TransCode Therapeutics Reports 2023 Results; Provides Business Update
BOSTON, April 03, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported financial results for 2023 and recent business progress. “We believe 2023 was extremely productive and pivotal for TransCode. We are proud to have advanced our lead therapeutic candidate, TTX-MC138, into the clinic as a first-in-class drug candidate against metastatic cancer. The year was highlighted
- GlobeNewswire
TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer
Medical oncologist brings over 25 years of industry experience to lead Clinical Development StrategyBOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, announced today that Daniel Vlock, M.D., has been appointed as the company’s Chief Medical Officer. Dr. Vlock is a medical oncologist with over 25 years of industry experience and 15 years in academia, including renow
